Navigation Links
Chesley Files Federal Zicam Lawsuits
Date:3/4/2010

CINCINNATI, March 4 /PRNewswire/ -- Stanley M. Chesley from the Cincinnati, Ohio-based law firm of Waite, Schneider, Bayless & Chesley Co., L.P.A. yesterday filed federal lawsuits in Ohio and Kentucky against Matrixx Initiatives, the manufacturer of Zicam, on behalf of four local residents who lost their senses of taste and smell after using the popular over-the-counter cold and flu nasal gel.

The lawsuits allege that Matrixx knew for years that Zicam users had complained of anosmia, or loss of smell, but explicitly chose not to warn Zicam customers.  

On June 16, 2009 the Food and Drug Administration issued a warning advising consumers to "stop using and discard" Zicam Cold Remedy Nasal Gel and Cold Remedy Nasal Swabs (among others) because Zicam is "associated with the loss of sense of smell."   In light of the FDA's warning, the lawsuit alleges, Matrixx had no choice but to immediately recall the dangerously defective Zicam products.

"The problem here is that Matrixx repeatedly refused to protect consumers of its products until the FDA forced its hand," noted Chesley.  "With these lawsuits, our clients intend to send a message that the American public will not stand by while another drug manufacturer secretly attempts to put its profits ahead of public safety."

The cases, Raker et al v. Matrixx Initiatives, Inc. et al., (Case Number 10-cv-000125, S.D. Ohio) and Hartman v. Matrixx Initiatives, Inc. et al., (Case Number 10-cv-00042, E.D. Ky.), allege negligence, defect in design and manufacture, failure to warn, breach of warranties, fraudulent concealment, and state consumer laws

CONTACT: Stanley M. Chesley, Robert A. Steinberg, or Renee A. Infante at (513) 621-0267

SOURCE Waite, Schneider, Bayless & Chesley Co., L.P.A.

Back to top
'/>"/>
SOURCE Waite, Schneider, Bayless & Chesley Co., L.P.A.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
4. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
7. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
8. FDA Files Application To Convert ONTAK(R) (Denileukin Diftitox) to Full Approval for Use in Cutaneous T-Cell Lymphoma (CTCL)
9. Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
10. ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
11. deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... North America , ... The global market is expected to reach USD 20,190.1 Million by ... of 10.2%. --> North America , ... MarketsandMarkets, The global market is expected to reach USD 20,190.1 Million ... CAGR of 10.2%. --> According to a new market ...
(Date:2/11/2016)... , February 11, 2016 ... Market Report 2016 research report provides information on ... development status with crucial statistical data and information ... http://www.deepresearchreports.com/142870.html . --> Complete report on ... companies and supported with 296 tables and figures ...
(Date:2/10/2016)... , Feb. 11, 2016  QT Vascular Ltd., together ... and together with its subsidiaries, the "Group"), is ... litigation with AngioScore, Inc. ("ÄngioScore") (now owned by ... the United States Court ... Circuit") reversed an earlier district court order (the ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... The Commission ... for the Board of Commissioners. Individuals interested in volunteer board service are encouraged ... of clinical practice settings and across allied health to contribute to its mission ...
(Date:2/11/2016)... ... February 11, 2016 , ... PharmMD ... Counsel. Garrett will focus on contract negotiations, corporate strategy and healthcare data law. ... and best practices in data breaches for the Part D Star Rating improvement ...
(Date:2/11/2016)... Orange City, FL (PRWEB) , ... February 11, ... ... has announced the commencement of a master charity program created to assist the ... every 60 days, working closely with nonprofit organizations and community leaders. Their hope ...
(Date:2/11/2016)... ... 11, 2016 , ... AccuVein Inc. announces the Infusion Nurses ... Practice, to include vascular visualization as a standard practice. AccuVein ( http://www.accuvein.com ), ... market, facilitates adherence to this standard with its easy to use, widely deployed ...
(Date:2/11/2016)... TX (PRWEB) , ... February 11, 2016 , ... ... surrounding communities with their ongoing community involvement program, introduces a new charity campaign ... hospitalized children, donations are now being accepted at https://donate.rmhc.org/ . , Ronald ...
Breaking Medicine News(10 mins):